Jane Street’s Adaptimmune Therapeutics ADAP Stock Holding History

Jane Street’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-93,600	Closed	-$484K	–	9974
2021 Q3	$484K	Buy	93,600 +62,700	+203%	+$281K	﹤0.01%	7339
2021 Q2	$132K	Buy	+30,900	New	+$150K	﹤0.01%	9130
2020 Q3	–	Sell	-21,800	Closed	-$218K	–	7073
2020 Q2	$218K	Buy	+21,800	New	+$137K	﹤0.01%	6256

Other funds holding ADAP

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return

Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Jane Street's ADAP Position: Q4 2025 in Review

Jane Street sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 2,805,345 shares — an estimated $365K sold.

Jane Street first reported a position in ADAP in Q1 2018 and held it in 12 quarters. The position peaked at $365K in Q3 2025. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

Jane Street reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
Jane Street sold 2,805,345 Adaptimmune Therapeutics shares in Q4 2025, an estimated $365K.
Jane Street first reported a position in Adaptimmune Therapeutics in Q1 2018 and held it in 12 quarters.
Jane Street's Adaptimmune Therapeutics position peaked at $365K in Q3 2025.
10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.